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Introduction
Montanide™ ISA 51 VG and Montanide™ ISA 720 VG
are adjuvants dedicated to human therapeutic vaccines.
The adjuvants are rendering stable water-in-oil (W/O)
emulsions when mixed with water phase. In these for-
mulations the active ingredients are entrapped in dro-
plets of water surrounded by continuous oil phase. It
allows a protection against degradation and slow release
of the active into the host. It can bring interesting prop-
erties for continuous stimulation of the immune system
or to minimize the toxicity of active ingredients.
In vitro slow release of protein
The proof of concept of the slow release is presented
through an in vitro experiment. A model Bovine Serum
Albumin (BSA) protein is placed into dialysis bags and
the quantity of released protein is measured by ELISA
technics. The release of the BSA formulated in W/O
emulsions is dramatically delayed as compared to the
BSA placed into saline solution.
In vivo release of caffeine
The effect of several W/O emulsions, based on Monta-
nide™ ISA 720 VG, on the release on a model caffeine
active are compared in vivo in rats. Rats were divided
into 3 groups containing 4 rats each. The first and sec-
ond groups were used as controls with intravenous and
subcutaneous injections respectively, of 1.5 to 2 ml of
aqueous solution containing 40 mg caffeine/kg. The third
group received subcutaneously 1.5 to 2 ml of a W/O
emulsion containing 40 mg caffeine/kg. The results show
that caffeine injected subcutaneously when emulsified is
absorbed in a differed way as compared to an aqueous
solution caffeine.
Applications to the release of antibodies
Formulations containing 3% of anti-ovalbumine (OVA)
hyper immune sera of mice have been injected to mice.
The kinetic apparition of IgG1 has been observed up to
42 days. W/O formulations are inducing a delayed
release of IgG1 as compared to non-formulated serum,
and are lowering the concentration of circulating anti-
body. Fransen et al. have emulsified anti CD40 antibo-
dies in Montanide™ ISA 51 VG. The slow release of
anti-CD40 could enhance both safety and immune sti-
mulation of the treatment
Conclusion
Montanide ™ISA 51 VG and Montanide™ ISA 720 VG
are vaccine adjuvants already tested in numerous clinical
trials. They are rendering W/O emulsions of which slow
release properties can be exploited for the administra-
tion of monoclonal or polyclonal antibodies. It can be
particularly interesting to use these well tolerated vehi-
cles in case of combination treatment for cancer in the
view of enhancing the safety of antibodies and associate
them to the immune stimulation of the adjuvanted
vaccine.
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